NEW YORK, NY / ACCESSWIRE / March 28, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Lexicon Pharmaceuticals, Inc. (NASDAQGS: LXRX)
Class Period: March 11, 2016 - January 17, 2019
Lead Plaintiff Deadline: April 1, 2019
Join the action: https://www.zlk.com/pslra-1/lexicon-pharmaceuticals-inc-loss-form?wire=3
The lawsuit alleges: Lexicon Pharmaceuticals, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the data from Lexicon's Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (ii) the health risks posed by Sotagliflozin were severe enough to threaten its U.S. Food & Drug Administration approval prospects; and (iii) as a result, Lexicon's public statements were materially false and misleading at all relevant times.
To learn more about the Lexicon Pharmaceuticals, Inc. class action contact [email protected].
Uxin Limited (NASDAQGS: UXIN)
Class Period: Pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the June 27, 2018 initial public offering
Lead Plaintiff Deadline: April 12, 2019
Join the action: https://www.zlk.com/pslra-1/uxin-limited-loss-form?wire=3
The Registration Statement was materially false and misleading and omitted to state that: (1) Uxin was likely to stop providing complementary services such as inspections to its customers; (2) instead, Uxin would connect consumers to dealers who would provide such complementary services; (3) as a result, Uxin's 2B business would be materially impacted; and (4) consequently, Defendants' statements in the Registration Statement regarding Uxin's business, operations, and prospects, were materially false and/or misleading.
To learn more about the Uxin Limited class action contact [email protected].
Corbus Pharmaceuticals Holdings, Inc. (NASDAQGM: CRBP)
Class Period: November 14, 2016 - February 28, 2019
Lead Plaintiff Deadline: May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?wire=3
The lawsuit alleges: Corbus Pharmaceuticals Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact [email protected].
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP